SCHEDULE 13G: BlackRock Discloses 5.2% Stake in Compass Therapeutics

BlackRock, Inc. has reported a 5.2% beneficial ownership stake in Compass Therapeutics, Inc. as of December 31, 2025, as disclosed in a Schedule 13G filing dated January 21, 2026.

Summary

• BlackRock, Inc. has filed a Schedule 13G, reporting beneficial ownership of 9,271,644 shares of Compass Therapeutics, Inc. common stock.
• This ownership represents 5.2% of the total outstanding common stock of Compass Therapeutics, Inc.
• BlackRock, Inc. holds sole voting power over 9,138,337 shares and sole dispositive power over 9,271,644 shares.
• The filing indicates that the shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing the control of Compass Therapeutics, Inc.
• Several BlackRock subsidiaries, including BlackRock Advisors, LLC and BlackRock Fund Advisors, are identified as entities that beneficially own 5% or greater of the outstanding shares of the security class.

Sentiment

Score: 6

Explanation: The filing indicates a significant institutional investment by BlackRock, which can be viewed as a vote of confidence, though it is a passive ownership disclosure and does not provide operational or financial performance data.

Positives

• BlackRock, Inc., a major institutional investor, has disclosed a 5.2% beneficial ownership stake in Compass Therapeutics, Inc., indicating significant institutional interest and potential confidence in the company.

Future Outlook

The filing does not contain any forward-looking statements or guidance from Compass Therapeutics, Inc. regarding its future performance or operations. It solely pertains to BlackRock's beneficial ownership position.

Management Comments

• "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect."

Industry Context

BlackRock's disclosure of a significant stake in Compass Therapeutics, a biotechnology company, highlights continued institutional interest in the life sciences sector. Such investments by major asset managers often signal a belief in the long-term potential of companies within innovative industries like biotech.

Stakeholder Impact

• Shareholders of Compass Therapeutics, Inc. may view BlackRock's significant stake as a positive indicator of institutional confidence in the company's long-term prospects.

Key Dates

Recommendation

The filing indicates a significant passive ownership stake by BlackRock, a major institutional investor. While this suggests institutional confidence, the Schedule 13G itself does not provide operational or financial performance data to warrant a stronger recommendation. Investors should consider this as a data point supporting a 'hold' position, pending further fundamental analysis of Compass Therapeutics' business and financials.

Keywords

BlackRock, Compass Therapeutics, CTIC, Schedule 13G, beneficial ownership, institutional investment, common stock, passive investment